In addition to its role in bone turnover, osteoprotegerin (OPG) has been reported to bind to
and inhibit Tumour necrosis factor-related apoptosis inducing ligand (TRAIL). TRAIL is�…

Osteoprotegerin (OPG) is a secreted protein and member of the Tumor Necrosis Factor
(TNF) Receptor superfamily. OPG has been well characterized as a regulator of bone�…

Osteoprotegerin (OPG) is a decoy receptor for receptor activator of NF‐κB ligand (RANKL)
and TNF‐related apoptosis‐inducing ligand (TRAIL). While RANKL is essential for�…

Advanced breast cancer is often associated with metastatic bone disease, causing a number
of serious complications for the patients such as hypercalceamia, pain, nerve compression�…

Background: Osteoprotegerin (OPG) is involved in the regulation of bone turnover through
binding to the receptor activator of nuclear factor κB ligand (RANKL), and has also been�…

Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor (TNF) receptor
superfamily that has been well characterized as a negative regulator of bone remodeling�…

Osteoprotegerin (OPG) is a soluble decoy receptor for tumor necrosis factor (TNF)-related
apoptosis inducing ligand (TRAIL). It belongs to the tumor necrosis factor receptor�…

Breast cancer cells preferentially metastasize to bone, leading to the formation of primarily
osteolytic lesions. Osteoprotegerin (OPG) plays multifactorial roles in the development of�…

Background: Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor family, is
produced by various cell types and tissues and plays a key role in the physiological�…

OPG (osteoprotegerin), a secreted member of the TNF (tumour necrosis factor) receptor
superfamily, has a variety of biological functions which include the regulation of bone�…